Iterum Therapeutics plc (NasdaqCM:ITRM) provided a general business update. Iterum plans to engage a financial advisor in the near-term to assist management and the Board in evaluating Iterum?s strategic alternatives.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.576 USD | +1.65% | 0.00% | -21.83% |
Apr. 29 | Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem | CI |
Mar. 28 | Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.83% | 25.66M | |
+21.76% | 47.9B | |
+46.62% | 41.42B | |
-2.18% | 40.7B | |
-6.20% | 28.92B | |
+10.19% | 25.55B | |
-20.87% | 19.27B | |
-0.32% | 12.15B | |
+31.04% | 12.14B | |
-0.47% | 11.99B |
- Stock Market
- Equities
- ITRM Stock
- News Iterum Therapeutics plc
- Iterum Therapeutics Plans to Engage Financial Advisor to Evaluate Strategic Alternatives